Don't let it get away!
Keep track of the stocks that matter to you.
Help yourself with the Fool's FREE and easy new watchlist service today.
For $11 billion, a 59% premium above Pharmasset's all-time high, Gilead is getting PSI-7977, an oral treatment that doesn't require interferon injections and their nasty side effects. This is potentially a huge improvement over the current standard of care, such as recently approved drugs like Vertex Pharmaceuticals' (Nasdaq: VRTX ) Incivek and Merck's (NYSE: MRK ) Victrelis.
It's no surprise that Vertex is down 3% as of this writing and that Inhibitex (Nasdaq: INHX ) , with its oral hep-C candidate INX-189, is up 25%. INX-189 has shown excellent data so far, but it hasn't entered phase 3 trials yet. Oddly, Achillion (Nasdaq: ACHN ) , with three hep-C drugs in development, is up only 3%, but the stock saw shares pop last week when the company's CEO got the market excited about a potential buyout. And on a day when the Dow Jones Industrial Average (INDEX: ^DJI ) is down 316 points, being up is no small feat.
For Gilead, this is not an indictment of its own stable of hep-C drug candidates. The future of treatment of this disease will be drug cocktails, similar to Gilead's HIV treatments Atripla and the upcoming Quad. Pharmasset already had deals with Bristol-Myers Squibb and Johnson & Johnson to create combo products. Now Gilead will potentially get a cut of those products' sales, and also the chance to boost its own higher-margin offerings' chances of success.
The multibillion-dollar race for hepatitis C treatment supremacy is well under way. The best way to track the latest developments surrounding the companies mentioned above is to add them to our free My Watchlist feature:
- Add Pharmasset to My Watchlist.
- Add Gilead Sciences to My Watchlist.
- Add Vertex to My Watchlist.
- Add Merck to My Watchlist.
- Add Inhibitex to My Watchlist.
- Add Achillion to My Watchlist.
- Add Bristol-Myers Squibb to My Watchlist.
- Add Johnson & Johnson to My Watchlist.
If you think the billions at stake in hepatitis C treatments are a big deal, wait until you read The Motley Fool's special free report, "The Next Trillion Dollar Revolution." Don't miss out on your chance to profit from this massive market opportunity.